Curis (CRIS) Receives FDA Orphan Drug Designation for CUDC-907 as DLBCL Treatment
Tweet Send to a Friend
Curis (NASDAQ: CRIS) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE